Superparamagnetic Nanoparticle Clusters for Cancer Theranostics Combining Magnetic Resonance Imaging and Hyperthermia Treatment
Open Access
- 1 January 2013
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 3 (6), 366-376
- https://doi.org/10.7150/thno.5860
Abstract
Superparamagnetic nanoparticles (SPIONs) could enable cancer theranostics if magnetic resonance imaging (MRI) and magnetic hyperthermia treatment (MHT) were combined. However, the particle size of SPIONs is smaller than the pores of fenestrated capillaries in normal tissues because superparamagnetism is expressed only at a particle size H = 8 kA/m and f = 230 kHz (Hf = 1.8×109 A/m∙s) for 20 min. The tumors of the mice underwent local heating by application of an AC magnetic field. The temperature of the tumor was higher than the surrounding tissues by ≈6°C at 20 min after treatment. Thirty-five days after treatment, the tumor volume of treated mice was one-tenth that of the control mice. Furthermore, the treated mice were alive after 12 weeks; control mice died up to 8 weeks after treatment.Keywords
This publication has 28 references indexed in Scilit:
- Mechanism of Magnetic Relaxation Switching SensingACS Nano, 2012
- Relaxivity Optimization of a PEGylated Iron-Oxide-Based Negative Magnetic Resonance Contrast Agent for T2-Weighted Spin–Echo ImagingACS Nano, 2012
- The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapyChemical Society Reviews, 2012
- Magnetic Nanoparticle-Based Hyperthermia for Head & Neck Cancer in Mouse ModelsTheranostics, 2012
- Magnetic fluid hyperthermia: Focus on superparamagnetic iron oxide nanoparticlesAdvances in Colloid and Interface Science, 2011
- Investigation of In Vivo Targeting Kinetics of αvβ3-Specific Superparamagnetic Nanoprobes by Time-Resolved MRITheranostics, 2011
- In vitro measurements of temperature-dependent specific heat of liver tissueMedical Engineering & Physics, 2006
- Effect of pegylation on pharmaceuticalsNature Reviews Drug Discovery, 2003
- Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJournal of Controlled Release, 2000
- Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24Blood, 1997